Biotech stocks benefited from the normalisation of medical and health care activities, coupled with positive incentives from new product launches, mergers and acquisitions, OEM orders and foreign exchange gains in the pharmaceutical sector, resulting in good profits. The market will also see drug licenses from PharmaEngine , Oneness Biotech and Foresee Pharmaceuticals, which will encourage the stocks market.
It is believed that 2023 will be a turning year for medical stocks, with profits estimated to grow by another 30% thanks to the relaxation of the medical law and regenerative medicine regulations. According to preliminary statistics, Bora Pharmaceuticals, Lotus Pharma, Syn-Tech Chem & Pharm, Chunghwa Chemical Synthesis & Biotech, Standard Chem & Pharm, TTY Biopharm, PBF, Oneness Biotech, SCI Pharmtec, Nang Kuang Pharmaceutical, PharmaEngine and Ever Supreme Biotechnology , etc., are bullish in terms of profits.
PharmaEngine's new pancreatic cancer drug, ONIVYDE, has been in the forefront of the market. After meeting the Phase III clinical target, the company is optimistic that its strategic partners will apply for drug licenses in the first quarter of 2023, and will also apply for Taiwan and European drug approval in the second and third quarters.
Medical-device stocks are benefiting from the global market returning to normal. Companies such as Delta Asia, TaiDoc, Yee Yee Titanium, Intai Technology, United Orthopedic, Onyx Healthcare, BIOTEQ and Pacific Hospital Supply, etc., have regained growth in the second half of 2022 and have a positive outlook for the first half of 2023.
For Wellell, the orders in H1, 2023 for air mattresses from large Italian hospitals will contribute about 3.5 million to 4 million euros in revenue. It will rank among the top three in the world within 5 years, and its market share will double. In the first three quarters of 2022, Delta Asia was facing headwinds, and the EPS was still at the level of NT$5. In order to meet customer needs, a new plant will be built. The production capacity will be 10 times that of the old plant.
Among the beauty and health care products group, companies anticipated bullish on the post-epidemic business opportunities are TCI, Grape King, Chlitina Holding, Luo Lih-Fen Holding, Jourdeness Spa, Dr. Wu and Shiny Brands.
And it is expected Grape King in Shanghai's revenue to grow by more than 30% year-on-year in 2023, with net earnings per share challenging new highs.
另法人估，大江2023年毛利率將重回年增，預期營收年增率可望轉正，獲利增幅高於營收。
In addition, the company estimates that DJI's gross margin will return to annual growth in 2023, and expects revenue growth to turn positive and profit growth to be higher than revenue.
